在确诊时的转化预示相对较好的预后，5年无进展生存率和总生存率分别达到66%和88%。
Transformation at the time of diagnosis portends a more favorable prognosis with 5-year PFS and OS rates of 66% and 88%, respectively.
二级终点包含了目标反应率，一年生存期，总生存率，化疗类型和安全性PFS评估。
Secondary endpoints included objective response rate, one-year survival rate, overall survival, PFS assessment by chemotherapy type and safety.
主要效果终端指标为总生存率和症状进展时间。
Primary efficacy endpoints were overall survival and time to symptomatic progression.
预后参数评估包括总生存率和肿瘤相关生产率。
The outcome parameters assessed were overall survival and tumor-related survival.
尽管对已知的危险因素和随访措施改进不少，但胃癌患者的总生存率仍然很差。
The overall survival of gastric carcinoma patients remains poor despite improved control over known risk factors and surveillance.
医生发现，与只接受同步放化疗的患者相比，接受诱导治疗和同步放化疗的患者，其总生存率升高较小，但很显著。
Doctors found a small but significant increase in overall survival in the patients who received the induction therapy with chemoradiation versus the chemoradiation-only group.
共同的初级终点指标为总生存率和无进展生存率。
Coprimary end points were rates of overall and progression-free survival.
共同的初级终点指标为总生存率和无进展生存率。
Coprimary end points were rates of overall and progression-free survival.
应用推荐